| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $4.26 | - | - |
| Q4'25 | $4.09 | $4.70 | +14.8% |
| Q4'24 | $2.83 | $3.44 | +21.5% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $5.5B | - | - |
| Q4'25 | $5.5B | $5.5B | +0.0% |
| Q4'24 | - | $5.1B | - |
Market Data
THC is currently trading at $225.00, giving Tenet Healthcare Corporation a market cap of 16.93B and a P/E ratio of 9.9. Today's range spans $191.76–$232.99, with shares opening at $194.48 and moving up $25.91 (13.0%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 53/100.
Over the past year THC has traded between $146.60 and $247.21 - the current price is +53.5% off the 52-week low and -9.0% from the high. 29 analysts cover the stock with a Buy consensus and a mean 12-month target of $243.43 (range $210.00–$288.00), implying upside of +8.2%.
Relative strength is the story for Tenet Healthcare Corporation (THC) in Healthcare right now. Technical score 82/100 (BUY), sentiment neutral at 53/100, price $225.00 (in the upper portion of its 52-week range). The current P/E ratio stands at 9.9. The 16.93B market cap keeps this name on institutional screens, and the bullish setup means sector rotation inflows from Healthcare have a natural landing spot here. Annual range: $146.60–$247.21.
Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (82/100) and news sentiment (53/100, neutral) supports the narrative, analyst upgrades follow price rather than lead it. At $225.00 (in the upper portion of its 52-week range), THC's position within the $146.60–$247.21 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).